James P. Brady
Human Resources Officer bij SPERO THERAPEUTICS, INC.
Actieve functies van James P. Brady
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SPERO THERAPEUTICS, INC. | Human Resources Officer | - | - |
Loopbaan van James P. Brady
Eerdere bekende functies van James P. Brady
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
UNIQURE N.V. | Human Resources Officer | 01-08-2020 | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Human Resources Officer | 01-04-2015 | - |
Opleiding van James P. Brady
Harvard University | Graduate Degree |
Marietta College | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Nederland | 2 |
Operationeel
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- James P. Brady
- Ervaring